{"id":55107,"date":"2026-01-22T10:41:43","date_gmt":"2026-01-22T02:41:43","guid":{"rendered":"https:\/\/flcube.com\/?p=55107"},"modified":"2026-01-22T10:41:44","modified_gmt":"2026-01-22T02:41:44","slug":"henliuss-hlx701-gets-nmpa-nod-for-phase-ib-ii-advanced-crc-combination-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55107","title":{"rendered":"Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\/II Advanced CRC Combination Study"},"content":{"rendered":"\n<p><strong>Shanghai Henlius Biotech, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has approved a <strong>Phase\u202fIb\/II clinical study<\/strong> for <strong>HLX701<\/strong>, a <strong>SIRP\u03b1\u2011Fc fusion protein<\/strong>, in combination with <strong>cetuximab plus chemotherapy<\/strong> for <strong>advanced colorectal cancer (CRC)<\/strong>, advancing Henlius\u2019s <strong>CD47\u2011targeted immuno\u2011oncology pipeline<\/strong> into a <strong>key solid tumor indication<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Henlius Biotech, Inc. (2696.HK)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>HLX701 (SIRP\u03b1\u2011Fc fusion protein)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Phase\u202fIb\/II Clinical Trial Application (CTA)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced\/metastatic CRC (inoperable, post\u2011standard therapy failure)<\/td><\/tr><tr><td><strong>Regimen<\/strong><\/td><td>HLX701 + cetuximab + chemotherapy<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>16\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Exclusive China (ex\u2011Taiwan), Southeast Asia, Middle East, North Africa (licensed from FBD Biologics, 2023)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>SIRP\u03b1\u2011Fc fusion protein<\/strong> that <strong>binds CD47<\/strong> on tumor cells, blocking the <strong>\u201cdon\u2019t eat me\u201d inhibitory signal<\/strong><\/li>\n\n\n\n<li><strong>Effect:<\/strong> <strong>Promotes macrophage\u2011mediated phagocytosis<\/strong> of tumor cells and <strong>enhances anti\u2011tumor activity<\/strong><\/li>\n\n\n\n<li><strong>Advantage:<\/strong> <strong>Fc domain<\/strong> enables <strong>ADCC (antibody\u2011dependent cellular cytotoxicity)<\/strong> and <strong>CDC (complement\u2011dependent cytotoxicity)<\/strong>, potentially improving efficacy vs. pure CD47 blockers<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong><\/li>\n\n\n\n<li><strong>Cetuximab<\/strong> (EGFR inhibitor) <strong>sensitizes tumor cells<\/strong> to macrophage attack<\/li>\n\n\n\n<li><strong>Chemotherapy<\/strong> induces <strong>immunogenic cell death<\/strong>, increasing CD47 expression and tumor antigen presentation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China CRC Market<\/th><th>CD47 Inhibitor Landscape<\/th><\/tr><\/thead><tbody><tr><td><strong>Advanced CRC Patients (2026E)<\/strong><\/td><td>180,000<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Failed Standard Therapy<\/strong><\/td><td>54,000<\/td><td>\u2013<\/td><\/tr><tr><td><strong>EGFR\u2011Expressing (Cetuximab\u2011Eligible)<\/strong><\/td><td>32,000<\/td><td>\u2013<\/td><\/tr><tr><td><strong>HLX701 Addressable Market<\/strong><\/td><td>32,000<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Peak Market Share<\/strong><\/td><td>0%<\/td><td>15%<\/td><\/tr><tr><td><strong>Annual Cost (USD)<\/strong><\/td><td>\u2013<\/td><td>$45,000<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>\u2013<\/td><td>$216\u202fmillion (KRAS\u2011wildtype CRC segment)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Magrolimab<\/strong> (Gilead) \u2013 CD47 inhibitor, Phase\u202fIII in AML\/MDS, <strong>solid tumor trials ongoing<\/strong><\/li>\n\n\n\n<li><strong>Lemzoparlimab<\/strong> (I\u2011Mab) \u2013 CD47 inhibitor, Phase\u202fII, <strong>no CRC data yet<\/strong><\/li>\n\n\n\n<li><strong>Evorpacept<\/strong> (ALX Oncology) \u2013 SIRP\u03b1\u2011Fc fusion (similar to HLX701), <strong>Phase\u202fI\/II in solid tumors<\/strong><\/li>\n\n\n\n<li><strong>HLX701<\/strong> \u2013 <strong>First CD47\u2011targeted agent<\/strong> entering <strong>Phase\u202fII\u2011ready study in combination with cetuximab<\/strong> for CRC<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-next-steps\">Strategic Positioning &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Henlius\u2019s <strong>Shanghai biologics facility<\/strong> (capacity 10,000\u202fL) will produce HLX701 clinical supply; <strong>scale\u2011up to 30,000\u202fL<\/strong> planned for commercial launch<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> <strong>Phase\u202fIb\/II dose\u2011escalation and expansion<\/strong> planned <strong>Q2\u202f2026<\/strong>; primary endpoint: <strong>ORR by RECIST 1.1<\/strong>; secondary: <strong>PFS, OS, safety<\/strong><\/li>\n\n\n\n<li><strong>Commercial Reach:<\/strong> <strong>800\u2011person oncology sales force<\/strong> already detailing <strong>cetuximab biosimilar<\/strong> and <strong>PD\u20111 inhibitor<\/strong>; <strong>cross\u2011selling HLX701<\/strong> upon approval<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Henlius plans <strong>US IND filing<\/strong> for HLX701 in <strong>2027<\/strong>, leveraging China combination data; <strong>ex\u2011China licensing<\/strong> discussions underway for <strong>SEA and MENA markets<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for HLX701. Actual results may differ due to clinical trial outcomes, competitive dynamics, and manufacturing challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012000517_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026012000517_c.\"><\/object><a id=\"wp-block-file--media-3b257ad2-e5e7-48ac-a780-e52a6993cda8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012000517_c.pdf\">2026012000517_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012000517_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3b257ad2-e5e7-48ac-a780-e52a6993cda8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China\u2019s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,270,862],"class_list":["post-55107","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-henlius-biotech","tag-hkg-2696"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\/II Advanced CRC Combination Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fIb\/II clinical study for HLX701, a SIRP\u03b1\u2011Fc fusion protein, in combination with cetuximab plus chemotherapy for advanced colorectal cancer (CRC), advancing Henlius\u2019s CD47\u2011targeted immuno\u2011oncology pipeline into a key solid tumor indication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55107\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\/II Advanced CRC Combination Study\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fIb\/II clinical study for HLX701, a SIRP\u03b1\u2011Fc fusion protein, in combination with cetuximab plus chemotherapy for advanced colorectal cancer (CRC), advancing Henlius\u2019s CD47\u2011targeted immuno\u2011oncology pipeline into a key solid tumor indication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55107\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T02:41:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T02:41:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55107#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55107\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\\\/II Advanced CRC Combination Study\",\"datePublished\":\"2026-01-22T02:41:43+00:00\",\"dateModified\":\"2026-01-22T02:41:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55107\"},\"wordCount\":433,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Henlius Biotech\",\"HKG: 2696\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55107#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55107\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55107\",\"name\":\"Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\\\/II Advanced CRC Combination Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T02:41:43+00:00\",\"dateModified\":\"2026-01-22T02:41:44+00:00\",\"description\":\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fIb\\\/II clinical study for HLX701, a SIRP\u03b1\u2011Fc fusion protein, in combination with cetuximab plus chemotherapy for advanced colorectal cancer (CRC), advancing Henlius\u2019s CD47\u2011targeted immuno\u2011oncology pipeline into a key solid tumor indication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55107#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55107\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55107#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\\\/II Advanced CRC Combination Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\/II Advanced CRC Combination Study - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fIb\/II clinical study for HLX701, a SIRP\u03b1\u2011Fc fusion protein, in combination with cetuximab plus chemotherapy for advanced colorectal cancer (CRC), advancing Henlius\u2019s CD47\u2011targeted immuno\u2011oncology pipeline into a key solid tumor indication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55107","og_locale":"en_US","og_type":"article","og_title":"Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\/II Advanced CRC Combination Study","og_description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fIb\/II clinical study for HLX701, a SIRP\u03b1\u2011Fc fusion protein, in combination with cetuximab plus chemotherapy for advanced colorectal cancer (CRC), advancing Henlius\u2019s CD47\u2011targeted immuno\u2011oncology pipeline into a key solid tumor indication.","og_url":"https:\/\/flcube.com\/?p=55107","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T02:41:43+00:00","article_modified_time":"2026-01-22T02:41:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55107#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55107"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\/II Advanced CRC Combination Study","datePublished":"2026-01-22T02:41:43+00:00","dateModified":"2026-01-22T02:41:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55107"},"wordCount":433,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Henlius Biotech","HKG: 2696"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55107#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55107","url":"https:\/\/flcube.com\/?p=55107","name":"Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\/II Advanced CRC Combination Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T02:41:43+00:00","dateModified":"2026-01-22T02:41:44+00:00","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China\u2019s National Medical Products Administration (NMPA) has approved a Phase\u202fIb\/II clinical study for HLX701, a SIRP\u03b1\u2011Fc fusion protein, in combination with cetuximab plus chemotherapy for advanced colorectal cancer (CRC), advancing Henlius\u2019s CD47\u2011targeted immuno\u2011oncology pipeline into a key solid tumor indication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55107#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55107"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55107#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius\u2019s HLX701 Gets NMPA Nod for Phase\u202fIb\/II Advanced CRC Combination Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55107"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55107\/revisions"}],"predecessor-version":[{"id":55112,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55107\/revisions\/55112"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}